Liquidia Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

Core Insights - Liquidia Corporation will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025, at 9:45 a.m. Pacific Time [1] - The presentation will be accessible via a live audio-only webcast on the company's investors page [2] Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for rare cardiopulmonary diseases [3] - The company is currently developing products for pulmonary hypertension using its proprietary PRINT Technology, including its lead candidate YUTREPIA™ (treprostinil) inhalation powder [3] - Liquidia is also working on L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for the treatment of pulmonary arterial hypertension (PAH) [3]